Oslo, Norway, 29 November 2011: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to announce that Torbjørn Øye has been engaged as interim Chief Financial Officer to support the Company until a permanent appointment has been made.
Torbjørn Øye has a long and successful track record in finance. He comes from Uniconsult AS and has a wide range of experience working in different functions within financial and accounting departments in large, medium and small sized, listed and unlisted companies. He holds a MBA from Norwegian School of Economics.
For further information contact:
President & CEO Kjetil Hestdal
Mary Clark, Amber Bielecka, Hollie Vile
About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology. Allumera®, Photocure® and Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit www.photocure.com.
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)